An Update on Impacts of Epigallocatechin Gallate Co-Administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers

• Published in: Planta Medica
• Main Author: Siew-Keah L.; Jie T.H.; Ang-Lim C.; Bin L.K.; Yik-Ling C.
• Format: Review
• Language: English
• Published: Georg Thieme Verlag 2023
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165256132&doi=10.1055%2fa-2111-7319&partnerID=40&md5=045a5e2fb98d68af10436bf2c5b57f3c

Brewed green tea, green tea extract, and its primary active compound, epigallocatechin gallate, may interact with drugs and alter the drugÊ s therapeutic effectiveness, ultimately leading to therapeutic failure or drug overdose. Several isolated reports have claimed that epigallocatechin gallate is the main active ingredient that causes these effects. While a few studies aimed to uncover evidence of epigallocatechin gallate-drug interactions, no study has thoroughly and collectively reviewed them. Epigallocatechin gallate is a potential cardioprotective agent used by many patients with cardiovascular diseases as a complementary medicine alongside conventional modern medications, either with or without the knowledge of their physicians. Therefore, this review focuses on the impact of concurrent epigallocatechin gallate supplementation on pharmacokinetics and pharmacodynamics of several commonly used cardiovascular drugs (statins, beta-blockers, and calcium channel blockers). The PubMed index was searched for key words related to this review, without year limit, and the results were analyzed for interactions of cardiovascular drugs with epigallocatechin gallate. This review concludes that epigallocatechin gallate increases systemic circulation of several statins (simvastatin, fluvastatin, rosuvastatin) and calcium channel blockers (verapamil), but decreases the bioavailability of beta-blockers (nadolol, atenolol, bisoprolol). Further studies on its clinical significance in affecting drug efficacy are required. © 2023 Georg Thieme Verlag. All rights reserved.